IceCure Medical (NASDAQ:ICCM) versus Medifocus (OTCMKTS:MDFZF) Head to Head Comparison

IceCure Medical (NASDAQ:ICCM) and Medifocus (OTCMKTS:MDFZF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Valuation and Earnings

This table compares IceCure Medical and Medifocus”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.67 million	22.98	-$14.65 million	($0.29)	-5.24
Medifocus	N/A	N/A	N/A	N/A	N/A

Medifocus has lower revenue, but higher earnings than IceCure Medical.

Institutional and Insider Ownership

0.6% of IceCure Medical shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for IceCure Medical and Medifocus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	0	0	1	1	3.50
Medifocus	0	0	0	0	0.00

IceCure Medical currently has a consensus target price of $2.70, suggesting a potential upside of 77.63%. Given IceCure Medical’s stronger consensus rating and higher probable upside, equities analysts clearly believe IceCure Medical is more favorable than Medifocus.

Profitability

This table compares IceCure Medical and Medifocus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-376.85%	-124.44%	-87.70%
Medifocus	N/A	N/A	N/A

Summary

IceCure Medical beats Medifocus on 7 of the 10 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Medifocus

Medifocus, Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company owns technology platforms, including Endo-thermotherapy platform, a catheter-based focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array (APA) Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia. In addition, the company is developing APA 1000, a minimally invasive breast cancer treatment system, which is in pivotal Phase-III clinical trials. The company has a license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy technology for the treatment of cancers and other diseases. Medifocus, Inc. is based in Toronto, Canada.